Healthcare >> CEO Interviews >> August 28, 2013
Christopher M. Starr, Ph.D., cofounded Raptor Pharmaceutical Corp. in 2005 and serves as the company’s Chief Executive Officer and member of its board of directors. In 1997, Dr. Starr co-founded BioMarin Pharmaceutical Inc., serving as Senior Vice President and Chief Scientific Officer. At BioMarin Pharmaceutical Inc., he led a scientific operations team to successfully develop commercial manufacturing processes for enzyme replacement products, and supervised the cGMP design, construction and licensing of a manufacturing facility. From 1991 to 1998, as Vice President of Research and Development at BioMarin Pharmaceutical Inc.'s predecessor company, Glyko, Inc., Dr. Starr supervised and directed research, development and commercial programs. As a National Research Council Associate at the National Institutes of Health, NIH, Dr. Starr studied nuclear membrane transport, cell surface receptor function and protein intracellular trafficking. Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in biochemistry and molecular biology from the State University of New York, Health Science Center, Syracuse. Profile
TWST: Let's start with a quick introduction to Raptor Pharmaceuticals and how it defines or positions itself in the biopharmaceutical space.
Dr. Starr: We started Raptor about seven